Economic evaluation of celecoxib, a new cyclo-oxygenase 2 specific inhibitor, in Switzerland. [electronic resource]
Producer: 20010412Description: 59-75 p. digitalISSN:- 1170-7690
- Anemia -- chemically induced
- Anti-Inflammatory Agents, Non-Steroidal -- adverse effects
- Anti-Ulcer Agents -- economics
- Arthritis -- drug therapy
- Celecoxib
- Clinical Trials as Topic
- Cost of Illness
- Cost-Benefit Analysis
- Cyclooxygenase Inhibitors -- economics
- Decision Trees
- Drug Therapy, Combination
- Duodenal Ulcer -- chemically induced
- Economics, Pharmaceutical
- Humans
- Probability
- Pyrazoles
- Sulfonamides -- economics
- Switzerland
No physical items for this record
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.